Pertuzumab: a new targeted therapy for HER2-positive metastatic breast cancer.
about
Harnessing the immune system to improve cancer therapyManagement of patients treated with pertuzumab in the Australian clinical practice setting.Cell-specific biomarkers and targeted biopharmaceuticals for breast cancer treatment.Degradable hyaluronic acid/protamine sulfate interpolyelectrolyte complexes as miRNA-delivery nanocapsules for triple-negative breast cancer therapy.A HER2 bispecific antibody can be efficiently expressed in Escherichia coli with potent cytotoxicity.Is there a role for immunotherapy in HER2-positive breast cancer?
P2860
Pertuzumab: a new targeted therapy for HER2-positive metastatic breast cancer.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Pertuzumab: a new targeted therapy for HER2-positive metastatic breast cancer.
@en
type
label
Pertuzumab: a new targeted therapy for HER2-positive metastatic breast cancer.
@en
prefLabel
Pertuzumab: a new targeted therapy for HER2-positive metastatic breast cancer.
@en
P2093
P2860
P356
P1433
P1476
Pertuzumab: a new targeted therapy for HER2-positive metastatic breast cancer.
@en
P2093
Chad M Barnett
Karen R Eckmann
Stephanie J Malenfant
P2860
P356
10.1002/PHAR.1338
P407
P577
2013-08-05T00:00:00Z